PMID- 28564559
OWN - NLM
STAT- MEDLINE
DCOM- 20170605
LR  - 20170605
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 376
IP  - 22
DP  - 2017 Jun 1
TI  - Minocycline in Multiple Sclerosis - Compelling Results but Too Early to Tell.
PG  - 2191-2193
LID - 10.1056/NEJMe1703230 [doi]
FAU - Xia, Zongqi
AU  - Xia Z
AD  - From the Program in Translational Neurology and Neuroinflammation, Pittsburgh
      Institute of Neurodegenerative Diseases (Z.X.), and the Institute of Multiple
      Sclerosis Care and Research, Department of Neurology (Z.X.), and the
      Neuroapoptosis Laboratory, Department of Neurosurgery (R.M.F.), University of
      Pittsburgh School of Medicine and University of Pittsburgh Medical Center - all
      in Pittsburgh.
FAU - Friedlander, Robert M
AU  - Friedlander RM
AD  - From the Program in Translational Neurology and Neuroinflammation, Pittsburgh
      Institute of Neurodegenerative Diseases (Z.X.), and the Institute of Multiple
      Sclerosis Care and Research, Department of Neurology (Z.X.), and the
      Neuroapoptosis Laboratory, Department of Neurosurgery (R.M.F.), University of
      Pittsburgh School of Medicine and University of Pittsburgh Medical Center - all
      in Pittsburgh.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - FYY3R43WGO (Minocycline)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2017 Jun 1;376(22):2122-2133. PMID: 28564557
MH  - *Minocycline
MH  - *Multiple Sclerosis
EDAT- 2017/06/01 06:00
MHDA- 2017/06/06 06:00
CRDT- 2017/06/01 06:00
PHST- 2017/06/01 06:00 [entrez]
PHST- 2017/06/01 06:00 [pubmed]
PHST- 2017/06/06 06:00 [medline]
AID - 10.1056/NEJMe1703230 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Jun 1;376(22):2191-2193. doi: 10.1056/NEJMe1703230.